274 related articles for article (PubMed ID: 27924158)
1. Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.
Roy M; Liang L; Xiao X; Peng Y; Luo Y; Zhou W; Zhang J; Qiu L; Zhang S; Liu F; Ye M; Zhou W; Liu J
Theranostics; 2016; 6(12):2209-2224. PubMed ID: 27924158
[TBL] [Abstract][Full Text] [Related]
2. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
Wang H; Gong Y; Liang L; Xiao L; Yi H; Ye M; Roy M; Xia J; Zhou W; Yang C; Shen X; Zhang B; Li Z; Liu J; Zhou H; Xiao X
Br J Haematol; 2020 Jun; 189(6):1151-1164. PubMed ID: 32167591
[TBL] [Abstract][Full Text] [Related]
3. Lycorine induces programmed necrosis in the multiple myeloma cell line ARH-77.
Luo Y; Roy M; Xiao X; Sun S; Liang L; Chen H; Fu Y; Sun Y; Zhu M; Ye M; Liu J
Tumour Biol; 2015 Apr; 36(4):2937-45. PubMed ID: 25487618
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MALAT-1 Elevates HMGB1 to Promote Autophagy Resulting in Inhibition of Tumor Cell Apoptosis in Multiple Myeloma.
Gao D; Lv AE; Li HP; Han DH; Zhang YP
J Cell Biochem; 2017 Oct; 118(10):3341-3348. PubMed ID: 28295550
[TBL] [Abstract][Full Text] [Related]
5. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
6. Lycorine induces cell death in MM by suppressing Janus Kinase/signal transducer and activator of transcription via inducing the expression of SOCS1.
Jin Z; Zhou S; Zhang Y; Ye H; Jiang S; Yu K; Ma Y
Biomed Pharmacother; 2016 Dec; 84():1645-1653. PubMed ID: 27847203
[TBL] [Abstract][Full Text] [Related]
7. HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair.
Guo X; He D; Zhang E; Chen J; Chen Q; Li Y; Yang L; Yang Y; Zhao Y; Wang G; He J; Cai Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):205. PubMed ID: 30157958
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest.
Li Y; Liu J; Tang LJ; Shi YW; Ren W; Hu WX
Oncol Rep; 2007 Feb; 17(2):377-84. PubMed ID: 17203177
[TBL] [Abstract][Full Text] [Related]
9. Lycorine possesses notable anticancer potentials in on-small cell lung carcinoma cells via blocking Wnt/β-catenin signaling and epithelial-mesenchymal transition (EMT).
Sun Y; Wu P; Sun Y; Sharopov FS; Yang Q; Chen F; Wang P; Liang Z
Biochem Biophys Res Commun; 2018 Jan; 495(1):911-921. PubMed ID: 29127013
[TBL] [Abstract][Full Text] [Related]
10. Lycorine improves peripheral nerve function by promoting Schwann cell autophagy via AMPK pathway activation and MMP9 downregulation in diabetic peripheral neuropathy.
Yuan Q; Zhang X; Wei W; Zhao J; Wu Y; Zhao S; Zhu L; Wang P; Hao J
Pharmacol Res; 2022 Jan; 175():105985. PubMed ID: 34863821
[TBL] [Abstract][Full Text] [Related]
11. Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1.
Li H; Roy M; Liang L; Cao W; Hu B; Li Y; Xiao X; Wang H; Ye M; Sun S; Zhang B; Liu J
Oncogene; 2022 Feb; 41(9):1298-1308. PubMed ID: 34997217
[TBL] [Abstract][Full Text] [Related]
12. MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma.
Zhang L; Rastgoo N; Wu J; Zhang M; Pourabdollah M; Zacksenhaus E; Chen Y; Chang H
Cancer Lett; 2020 Jun; 480():29-38. PubMed ID: 32220540
[TBL] [Abstract][Full Text] [Related]
13. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
[TBL] [Abstract][Full Text] [Related]
14. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
17. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
18. Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.
Vasuthasawat A; Yoo EM; Trinh KR; Lichtenstein A; Timmerman JM; Morrison SL
MAbs; 2016 Oct; 8(7):1386-1397. PubMed ID: 27362935
[TBL] [Abstract][Full Text] [Related]
19. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
Jagannathan S; Abdel-Malek MA; Malek E; Vad N; Latif T; Anderson KC; Driscoll JJ
Leukemia; 2015 Nov; 29(11):2184-91. PubMed ID: 26108695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
